IL319254A - תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג - Google Patents

תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג

Info

Publication number
IL319254A
IL319254A IL319254A IL31925425A IL319254A IL 319254 A IL319254 A IL 319254A IL 319254 A IL319254 A IL 319254A IL 31925425 A IL31925425 A IL 31925425A IL 319254 A IL319254 A IL 319254A
Authority
IL
Israel
Prior art keywords
kat2
pyridazinon
degraders
derivatives
treatment
Prior art date
Application number
IL319254A
Other languages
English (en)
Original Assignee
Auron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auron Therapeutics Inc filed Critical Auron Therapeutics Inc
Publication of IL319254A publication Critical patent/IL319254A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL319254A 2022-09-02 2023-09-01 תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג IL319254A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263403401P 2022-09-02 2022-09-02
US202363460764P 2023-04-20 2023-04-20
PCT/US2023/031835 WO2024050078A1 (en) 2022-09-02 2023-09-01 Pyridazinon derivatives as kat2 degraders for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
IL319254A true IL319254A (he) 2025-04-01

Family

ID=88192267

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319254A IL319254A (he) 2022-09-02 2023-09-01 תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג

Country Status (9)

Country Link
EP (1) EP4581025A1 (he)
JP (1) JP2025530801A (he)
KR (1) KR20250077607A (he)
CN (1) CN120112525A (he)
AU (1) AU2023333181A1 (he)
CA (1) CA3266556A1 (he)
IL (1) IL319254A (he)
MX (1) MX2025002519A (he)
WO (1) WO2024050078A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof
CN120794955A (zh) * 2025-07-07 2025-10-17 四川伊诺唯新生物医药有限公司 一种irak4靶向蛋白降解剂关键中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3189046B1 (en) 2014-09-05 2020-08-26 Genentech, Inc. Therapeutic compounds and uses thereof
EP3189049B1 (en) 2014-09-05 2024-03-20 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
EP3242874B1 (en) 2015-01-09 2018-10-31 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
AU2016349781A1 (en) * 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3947368B1 (en) * 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer

Also Published As

Publication number Publication date
JP2025530801A (ja) 2025-09-17
CN120112525A (zh) 2025-06-06
MX2025002519A (es) 2025-06-02
WO2024050078A1 (en) 2024-03-07
AU2023333181A1 (en) 2025-03-13
EP4581025A1 (en) 2025-07-09
KR20250077607A (ko) 2025-05-30
CA3266556A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
IL287280A (he) תרכובות ושיטות לטיפול בהפרעות עיניות
IL319254A (he) תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג
IL304595A (he) נגזרות טטרהידרוזפין ביציקליות לטיפול בסרטן
IL287264A (he) תרכובות ושיטות לטיפול בהפרעות עיניות
GB202020549D0 (en) Treatment for Lysine Degradation-associated Disorders
IL286756A (he) ליפוקלין מוטאין לטיפול באסטמה
PL4143179T3 (pl) Pochodne azetydyn-3-ylometanolu jako modulatory receptora ccr6 do leczenia nowotworu
EP4294388A4 (en) OXA-IBOGAIN ANALOGUES FOR THE TREATMENT OF SUBSTANCE ABUSE
EP4010347A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN AND ADDICTION DISORDERS
EP3883567B8 (en) Naphthyridinone-aniline compounds for treatment of dermal disorders
SG11202108636SA (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
IL289221A (he) תרכובות לטיפול בהפרעות ראייה
CA3261797A1 (en) (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
IL290540A (he) תרכובות המתאימות לטיפול ומניעה של דלדול שרירים ומצבים אחרים
IL321845A (he) נגזרות 1-אמינו-4-פנילפתלזין שימושיות לטיפול במחלות ניוון עצביות
IL290035A (he) תולדות פירידין כמאפנני tmem16a לשימוש בטיפול במצבים נשימתיים
IL288234A (he) תרכובות לטיפול בהפרעות עצביות-שריריות
EP4232458A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
GB202110563D0 (en) Device for the treatment of foot conditions
EP3777759A4 (en) Apparatus for treating surface of medical metal
EP4037689A4 (en) 18-MC ON SUBSTANCE ABUSE TREATMENT
GB202103887D0 (en) Compounds for the treatment of bone disorders
HK40106221A (en) Compounds for use in the treatment of hyperproliferative disorders
GB202101161D0 (en) Formulations for the treatment of tendinopathies
GB202001137D0 (en) Formulations for the treatment of tendinopathies